ArticleInternational journal of nanomedicine2015
Hemagglutinin-based polyanhydride nanovaccines against H5N1 influenza elicit protective virus neutralizing titers and cell-mediated immunity.
Article in International journal of nanomedicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 52 citations in OpenAlex.
- Nanoparticle-Based Antiviral Vaccines for Chickens: Recent Advances and Future Perspectives.Transboundary and emerging diseases · 2025Review
- Nanomedicine for the Treatment of Viral Diseases: Smaller Solution to Bigger Problems.Pharmaceutics · 2024Review
- A Glance on Nanovaccine: A Potential Approach for Disease Prevention.Current pharmaceutical biotechnology · 2024Review
- Swine influenza A virus: challenges and novel vaccine strategies.Frontiers in cellular and infection microbiology · 2024Review
- Novel nanoadjuvants balance immune activation with modest inflammation: implications for older adult vaccines.Immunity & ageing : I & A · 2023Article
- Polyanhydride Chemistry.Biomacromolecules · 2022Review
- Long-Lasting Protection Induced by a Polyanhydride Nanovaccine against Respiratory Syncytial Virus in an Outbred Mouse Model.Journal of virology · 2022Article
- Article
- Structural Stability and Antigenicity of Universal Equine H3N8 Hemagglutinin Trimer upon Release from Polyanhydride Nanoparticles and Pentablock Copolymer Hydrogels.ACS biomaterials science & engineering · 2022Article
- Nanovaccine Delivery Approaches and Advanced Delivery Systems for the Prevention of Viral Infections: From Development to Clinical Application.Pharmaceutics · 2021Review
- An Overview of Nanocarrier-Based Adjuvants for Vaccine Delivery.Pharmaceutics · 2021Review
- Polymeric Nanoparticle-Based Vaccine Adjuvants and Delivery Vehicles.Current topics in microbiology and immunology · 2021Review
- Article
- Anti-Influenza Strategies Based on Nanoparticle Applications.Pathogens (Basel, Switzerland) · 2020Review
- Influenza A Virus Vaccination: Immunity, Protection, and Recent Advances Toward A Universal Vaccine.Vaccines · 2020Review
- Advancements in prophylactic and therapeutic nanovaccines.Acta biomaterialia · 2020Review
- Polyanhydride Nanoparticles Induce Low Inflammatory Dendritic Cell Activation Resulting in CD8International journal of nanomedicine · 2020Article
- A single dose polyanhydride-based nanovaccine against paratuberculosis infection.NPJ vaccines · 2020Article
- Single-dose combination nanovaccine induces both rapid and long-lived protection against pneumonic plague.Acta biomaterialia · 2019Article
- Vitamin A deficiency impairs the immune response to intranasal vaccination and RSV infection in neonatal calves.Scientific reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
Abstract
H5N1 avian influenza is a significant global concern with the potential to become the next pandemic threat. Recombinant subunit vaccines are an attractive alternative for pandemic vaccines compared to traditional vaccine technologies. In particular, polyanhydride nanoparticles encapsulating subunit proteins have been shown to enhance humoral and cell-mediated immunity and provide protection upon lethal challenge. In this work, a recombinant H5 hemagglutinin trimer (H5₃) was produced and encapsulated into polyanhydride nanoparticles. The studies performed indicated that the recombinant H5₃ antigen was a robust immunogen. Immunizing mice with H5₃ encapsulated into polyanhydride nanoparticles induced high neutralizing antibody titers and enhanced CD4(+) T cell recall responses in mice. Finally, the H5₃-based polyanhydride nanovaccine induced protective immunity against a low-pathogenic H5N1 viral challenge. Informatics analyses indicated that mice receiving the nanovaccine formulations and subsequently challenged with virus were similar to naïve mice that were not challenged. The current studies provide a basis to further exploit the advantages of polyanhydride nanovaccines in pandemic scenarios.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.